Sign up
TRVN

Trevena Inc (NASDAQ: TRVN)

Healthcare · Biotechnology

$0.00

Last close · Nov 13, 2026 · NASDAQ USD

Set alert

The Quantellect read. The borrow fee is 26.82%. Descriptive summary of the data on this page, not a recommendation.

Relative valuationLower multiples than peers

P/S 0.0× vs peer median 13.9×

Momentum—

—

TrendBelow both averages

$0.00 vs $0.01 and $0.67 · as of Nov 13, 2026

Short interest—

FINRA settlement Oct 30, 2026

TRVN price chart

Price $0.00 · As of Nov 17, 2026, 8:49 PM ET

Open full chart →
Nov 13, 2026O $0.00H $0.00L $0.00C $0.00Vol 977

Chart loads when this section enters view.

Text price and event history
6M plotted price range (ET)
Range6M
First dateMay 27, 2026 ET
Last dateNov 13, 2026 ET
Open$0.00
High$1.50
Low$0.00
Close$0.00
Volume15,591
Plotted bars24

Plotted OHLCV bars

  1. May 27, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 308
  2. May 29, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 447
  3. Jun 4, 2026 ET · Open — · High — · Low — · Close $0.01 · Volume 19
  4. Jun 12, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 145
  5. Jun 16, 2026 ET · Open — · High — · Low — · Close $0.01 · Volume 10
  6. Jun 24, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 424
  7. Jun 25, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 559
  8. Jun 26, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 275
  9. Jul 9, 2026 ET · Open $0.01 · High $0.01 · Low $0.01 · Close $0.01 · Volume 106
  10. Jul 17, 2026 ET · Open $0.01 · High $0.01 · Low $0.01 · Close $0.01 · Volume 355
  11. Jul 20, 2026 ET · Open $0.01 · High $0.01 · Low $0.01 · Close $0.01 · Volume 4
  12. Aug 5, 2026 ET · Open $0.00 · High $1.50 · Low $0.00 · Close $0.00 · Volume 1,844
  13. Aug 17, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 109
  14. Aug 26, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 1,218
  15. Sep 9, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 346
  16. Sep 11, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 214
  17. Sep 25, 2026 ET · Open $0.01 · High $0.01 · Low $0.01 · Close $0.01 · Volume 2,282
  18. Sep 29, 2026 ET · Open $0.01 · High $0.01 · Low $0.01 · Close $0.01 · Volume 419
  19. Oct 5, 2026 ET · Open $0.01 · High $0.01 · Low $0.01 · Close $0.01 · Volume 194
  20. Oct 6, 2026 ET · Open $0.01 · High $0.01 · Low $0.01 · Close $0.01 · Volume 257
  21. Oct 12, 2026 ET · Open $0.07 · High $0.07 · Low $0.07 · Close $0.07 · Volume 833
  22. Oct 16, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 4,129
  23. Nov 10, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 117
  24. Nov 13, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 977

Event records

Event records load after the price chart.

Split-adjusted daily prices · Price as of Nov 17, 2026, 8:49 PM ET

Initial 6M price range summary
Range6M
First close$0.00
Last close$0.00
High$1.50
Low$0.00
Volume15,591
Open
—Historical · Nov 13, 2026
Previous close
—Historical · Nov 13, 2026
Day range
—Historical · Nov 13, 2026
52-week range
—Through Nov 16, 2026
Volume
—Historical · Nov 13, 2026
Average volume (30 calendar days, 3 sessions)
1.74KThrough Nov 16, 2026
Market cap$9.59K
P/E (TTM)negative earnings —
Forward P/E—
EPS (TTM)stale vendor snapshot —
Dividend yielddata unavailable —
Beta (5-year monthly vs SPY)−1.57

Price history

TRVN · nasdaq · USD

Last completed session: Nov 13, 2026

Split-adjusted · volume in shares

Missing sessions: Nov 2, 2026, Nov 3, 2026, Nov 4, 2026, Nov 5, 2026, Nov 6, 2026, Nov 9, 2026, Nov 11, 2026, Nov 12, 2026, Nov 16, 2026, Nov 17, 2026

November 2026 · 2 completed sessions
DateOpenHighLowCloseChangeVolume
0.00050.00050.00050.0005—977
Open 0.0005High 0.0005Low 0.0005
0.00040.00040.00040.0004—117
Open 0.0004High 0.0004Low 0.0004

Notable price movement

Sessions where the close moved at least twice its average daily move of the prior 20 sessions (minimum 3%), or 10% or more.

  1. $0.00+25.00%

    Trading volume was 0.5 times the 30-day average, with 977 shares traded.

  2. $0.00−20.00%

    Trading volume was 0.0 times the 30-day average, with 117 shares traded.

  3. $0.00−99.24%

    Trading volume was 5.2 times the 30-day average, with 4.13K shares traded.

Options flow

— · Options flow not available

Q Score

—/100—

Latest available: Nov 13, 2026 · updates irregularly

Each axis is a 0 to 100 percentile rank among equities

Not scored: Equity peers

LiquidityNot scoredShortNot scoredSqueezeNot scoredTrendNot scoredMomentumNot scoredValuationNot scoredStabilityNot scored
What each one means
  • LiquidityNot scored

    Higher scores reflect greater average dollar trading volume and less absolute return per dollar traded over 21 sessions within equity peers.

  • ShortNot scored

    Higher scores reflect less short-interest pressure relative to trading volume and the company's own history, and less growth in shares short, within equity peers.

  • SqueezeNot scored

    Higher scores reflect a higher published Squeeze score within equity peers.

  • TrendNot scored

    Higher scores reflect a price nearer its 252-session split-adjusted closing high and positive 63- and 126-session total returns.

  • MomentumNot scored

    Higher scores reflect stronger 63- and 126-session total returns within equity peers.

  • ValuationNot scored

    Higher scores reflect lower positive P/E, P/B, EV/EBITDA and price/sales multiples within equity peers; limited data pulls the score toward neutral.

  • StabilityNot scored

    Higher scores reflect lower daily total-return volatility over 63 and 252 sessions within equity peers.

How the Q Score works →

Quantellect signals

Change since Nov 17

Insufficient data · Tide session Nov 17, 2026

Tide63High Tide—
Squeeze47Watch—
How the scores work →

How TRVN compares with its industry

Against 592 other US-listed Biotechnology stocks

Dot = rank among peers, low to high · tick = peer median · colour marks the top and bottom 10%

Strongest points

  1. Latest-quarter year-over-year sales growth was 57.2%, higher than 84% of 592 peers.Peer median 0.0% · As of Nov 17, 2026

Points of caution

  1. Trailing-year net margin was 0%, with only 19% of 583 peers reporting a lower value.Peer median 0.0% · As of Nov 17, 2026

Valuation

Lower multiples than peers

  • Price/sales0.02×13.90×
    Lowest 10%

    Higher than 1% of 407 peers

  • Forward P/E—14.90×

    Not ranked: only 194 of 592 peers report it

  • Price/book0.36×2.58×
    Lowest 10%

    Higher than 8% of 551 peers

Profitability

Profitability metrics are lower than most peers.

  • Gross margin—78.4%

    Not ranked: only 247 of 592 peers report it

  • Operating margin—0.0%

    Not ranked: only 443 of 592 peers report it

  • Net margin0.0%0.0%

    Higher than 19% of 583 peers

  • Return on equity—−67.9%

    Not ranked: only 555 of 592 peers report it

Growth

Growth metrics are higher than most peers.

  • Quarterly sales growth, year over year57.2%0.0%

    Higher than 84% of 592 peers

  • 5-year sales growth rate—11.3%

    Not ranked: only 140 of 592 peers report it

Balance sheet

Not enough peers report balance sheet metrics for a group comparison.

  • Current ratio—5.01

    Not ranked: only 499 of 592 peers report it

  • Debt/equity (total borrowings)—0.23

    Not ranked: only 117 of 592 peers report it

Momentum

Not enough peers report returns for a group comparison.

  • 1-year return—−29.8%

    Not ranked: only 523 of 592 peers report it

  • 6-month return—−24.0%

    Not ranked: only 548 of 592 peers report it

  • 3-month return—−31.6%

    Not ranked: only 560 of 592 peers report it

Compared with 592 other US-listed Biotechnology stocks · fundamentals as of Nov 1, 2026 · prices as of Nov 12, 2026

Upcoming events

— · Upcoming events not available

Analyst consensus

— · Analyst consensus not available

Earnings history

— · Earnings history not available

Smart-money activity

In the last 60 days: 0 insider sales and 0 purchases. No congressional trades in 90 days.

DateTypeWhoActionAmountSource
Insider sellShin BarrySell$13.0KForm 4
Insider buyBourdow Carrie L.Buy$100.5KForm 4
Insider buyHamill John P.Buy$8.7KForm 4
Insider buyGOWEN MAXINEBuy$51KForm 4
Insider buyMOULDER LEON O JRBuy$102KForm 4
Insider sellHabib YacoubSell$8.8KForm 4
Insider sellLark Michael W.Sell$189.6KForm 4
Insider buyBourdow Carrie L.Buy$17.4KForm 4
Insider buyGOWEN MAXINEBuy$51.2KForm 4
Insider buyHabib YacoubBuy$20.6KForm 4
All smart-money activity →

News and press releases

News and press releases are not available.

All TRVN news →

Company profile

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV734, a small molecule G protein biased ligand of the MOR, which has completed phase I studies for the treatment of moderate-to-severe acute and chronic

CEO
Ms. Carrie L. Bourdow
Headquarters
Chesterbrook, PA, United States
Employees
23
IPO date
Jan 31, 2014
Sector
Healthcare
Industry
Biotechnology

Data sources: exchange quotes delayed 15 minutes, FINRA short interest, SEC filings, OPRA options data and third-party analyst data. Education only. Nothing on this page is a recommendation to buy or sell a security.